[go: up one dir, main page]

MX2018012143A - Métodos de diagnóstico para la toma de decisiones terapéuticas específicas del paciente en el cuidado del cáncer. - Google Patents

Métodos de diagnóstico para la toma de decisiones terapéuticas específicas del paciente en el cuidado del cáncer.

Info

Publication number
MX2018012143A
MX2018012143A MX2018012143A MX2018012143A MX2018012143A MX 2018012143 A MX2018012143 A MX 2018012143A MX 2018012143 A MX2018012143 A MX 2018012143A MX 2018012143 A MX2018012143 A MX 2018012143A MX 2018012143 A MX2018012143 A MX 2018012143A
Authority
MX
Mexico
Prior art keywords
decision making
diagnostic methods
patient specific
specific therapeutic
therapeutic decision
Prior art date
Application number
MX2018012143A
Other languages
English (en)
Inventor
Erzsébet Pongrácz Judit
RAPP Judit
Rácz Evelin
Original Assignee
Humeltis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humeltis filed Critical Humeltis
Publication of MX2018012143A publication Critical patent/MX2018012143A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un agregado de cultivo tisular tridimensional de células derivadas de una muestra de tejido neoplásico, en donde (3D) 30% del número total de células son células capaces de interferir con la reagregación. También se relaciona con un método para hacer tal agregado 3D y un método para evaluar la efectividad de un tratamiento anti-neoplasmático midiendo el efecto de dicho tratamiento sobre la viabilidad de un agregado de cultivo tisular de neoplasia tridimensional (3D).
MX2018012143A 2016-04-04 2017-04-04 Métodos de diagnóstico para la toma de decisiones terapéuticas específicas del paciente en el cuidado del cáncer. MX2018012143A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201605759 2016-04-04
PCT/EP2017/058034 WO2017174609A1 (en) 2016-04-04 2017-04-04 Diagnostic methods for patient specific therapeutic decision making in cancer care

Publications (1)

Publication Number Publication Date
MX2018012143A true MX2018012143A (es) 2019-10-09

Family

ID=58609360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012143A MX2018012143A (es) 2016-04-04 2017-04-04 Métodos de diagnóstico para la toma de decisiones terapéuticas específicas del paciente en el cuidado del cáncer.

Country Status (13)

Country Link
US (1) US20190128870A1 (es)
EP (1) EP3440199A1 (es)
JP (1) JP2019513418A (es)
KR (1) KR20190003549A (es)
CN (1) CN109563486A (es)
AU (1) AU2017245629A1 (es)
CA (1) CA3019873A1 (es)
IL (1) IL262121A (es)
MX (1) MX2018012143A (es)
PH (1) PH12018502147A1 (es)
RU (1) RU2018138503A (es)
SG (1) SG11201808762XA (es)
WO (1) WO2017174609A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
CN116790476A (zh) 2016-05-05 2023-09-22 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
EP3534907A4 (en) 2016-11-04 2020-06-24 Children's Hospital Medical Center COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
CN108130313B (zh) * 2017-12-28 2021-04-30 杭州枫霖科技有限公司 一种基于生物3d打印构建三维胶质瘤组织的方法
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
US12428622B2 (en) 2018-09-12 2025-09-30 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
KR102030127B1 (ko) 2019-01-10 2019-10-08 주식회사 보타닉센스 운데칸 또는 운데칸알을 유효성분으로 포함하는 항알러지, 아토피 피부염 개선, 또는 피부 재생용 조성물
AU2020283048A1 (en) 2019-05-31 2021-12-23 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
US12497597B2 (en) 2019-05-31 2025-12-16 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
DE102019132865B4 (de) * 2019-12-03 2022-01-20 Precomb Therapeutics Ag Verfahren und vorrichtung für die analyse von gewebeproben
CN111690615B (zh) * 2020-06-12 2022-10-25 江苏信安佳医疗科技有限公司 一种鼻咽癌类器官专用培养基及无支架培养方法
KR102577816B1 (ko) * 2022-06-08 2023-09-12 차의과학대학교 산학협력단 암 미세환경 모사 췌장암 오가노이드의 제조방법 및 이의 용도
CN117625541B (zh) * 2024-01-26 2024-04-02 零壹人工智能科技研究院(南京)有限公司 一种脑胶质瘤类器官构建方法及药敏检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0900819A2 (en) * 2009-05-05 2011-01-28 Pecsi Tudomanyegyetem Lung tissue culture
EP2450707B1 (en) * 2010-11-04 2016-04-27 University of Pécs Lung tissue model
JP5774496B2 (ja) 2010-01-19 2015-09-09 株式会社ルネッサンス・エナジー・インベストメント 癌組織由来細胞塊または癌細胞凝集塊の培養方法、評価方法および保存方法
GB201100180D0 (en) * 2011-01-06 2011-02-23 Capsant Neurotechnologies Ltd Tumour cell and tissue culture
US20140128272A1 (en) 2012-11-08 2014-05-08 Osaka Prefectural Hospital Organization Method for Inducing Dormancy of Cancer Tissue-Derived Cell Mass and Method for Evaluating Treating Means with the Use of Cancer-Tissue-Derived Cell Mass
US10545133B2 (en) 2013-05-13 2020-01-28 The Johns Hopkins University Molecular signatures of invasive cancer subpopulations
US20160123960A1 (en) 2013-06-10 2016-05-05 Millennium Pharmaceuticals, Inc. Method for preparing three-dimensional, organotypic cell cultures and uses thereof
WO2015073724A1 (en) 2013-11-15 2015-05-21 Molecular Response, Llc 3d cell culture and ex vivo drug testing methods
TWI486451B (zh) * 2013-12-11 2015-06-01 Ind Tech Res Inst 經分離之人類肝癌細胞株及化合物篩選方法
TWI461535B (zh) * 2013-12-11 2014-11-21 Ind Tech Res Inst 經分離之人類肝癌細胞株及化合物篩選方法
CN106574242B (zh) 2014-06-20 2021-01-15 新泽西鲁特格斯州立大学 源自单细胞的类器官
WO2016022830A1 (en) 2014-08-06 2016-02-11 Oregon Health & Science University Three-dimensional bioprinted pancreatic tumor model
CN105062973B (zh) * 2015-07-22 2018-04-17 中山大学 一株携带tp53突变的hpv阴性阴茎鳞癌细胞系及其用途

Also Published As

Publication number Publication date
EP3440199A1 (en) 2019-02-13
SG11201808762XA (en) 2018-11-29
JP2019513418A (ja) 2019-05-30
RU2018138503A (ru) 2020-05-12
AU2017245629A1 (en) 2018-11-22
KR20190003549A (ko) 2019-01-09
PH12018502147A1 (en) 2019-07-15
IL262121A (en) 2018-11-29
US20190128870A1 (en) 2019-05-02
CA3019873A1 (en) 2017-10-12
CN109563486A (zh) 2019-04-02
WO2017174609A1 (en) 2017-10-12
RU2018138503A3 (es) 2020-08-18

Similar Documents

Publication Publication Date Title
PH12018502147A1 (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
AU2018256508A1 (en) Individualized vaccines for cancer
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MY197809A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
MX2018010261A (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
PH12017502153A1 (en) Diagnostic methods for t cell therapy
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
MA52909A (fr) Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
SA518391121B1 (ar) 18f مثبطات موسومة بواسطة (psma) في مستضد الغشاء الخاص بالبروستاتا واستخدامها كعوامل تصوير تشخيصي لحالات سرطان البروستاتا
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
NZ723884A (en) Methods of treating alzheimer’s disease
BR112013000433A2 (pt) diagnóstico e tratamento de câncer de mama
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
TW201614237A (en) Markers for identifying patients responsive to anti-PD-L1 antibody therapy
MX2021009247A (es) Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1.
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
MY200803A (en) Mpo inhibitors for use in medicine
IN2014DN08312A (es)
EA201791442A1 (ru) Способы лечения гематологических нарушений, солидных опухолей или инфекционных заболеваний с применением естественных клеток-киллеров